Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Total Liabilities (2019 - 2025)

Avidity Biosciences' Total Liabilities history spans 7 years, with the latest figure at $269.4 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 93.94% year-over-year to $269.4 million; the TTM value through Dec 2025 reached $269.4 million, up 93.94%, while the annual FY2025 figure was $269.4 million, 93.94% up from the prior year.
  • Total Liabilities reached $269.4 million in Q4 2025 per RNA's latest filing, up from $247.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $269.4 million in Q4 2025 to a low of $26.0 million in Q2 2021.
  • Average Total Liabilities over 5 years is $98.8 million, with a median of $58.2 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: tumbled 59.65% in 2021, then soared 146.68% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $46.2 million in 2021, then surged by 31.58% to $60.7 million in 2022, then soared by 110.44% to $127.8 million in 2023, then increased by 8.72% to $138.9 million in 2024, then soared by 93.94% to $269.4 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Total Liabilities are $269.4 million (Q4 2025), $247.9 million (Q3 2025), and $176.3 million (Q2 2025).